Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + bevacizumab + nab-paclitaxel + carboplatin for untreated cancer of unknown primary
ChiCTR2300073699Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jul 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, bevacizumab, paclitaxel and carboplatin in cancer of unknown primary (CUP), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: progression-free survival. Started Jul 2023; status: recruiting.
02
Drugs
sintilimabbevacizumabpaclitaxelcarboplatin
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on ChiCTR2300073699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073699.